IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model

Prohibitin, which can inhibit oxidative stress and mitochondrial dysfunction, has been shown to have significant anti-inflammatory activities. Here, we investigate the effects of altering prohibitin levels in affected tissues in the interleukin-10 knockout (IL-10KO) mouse model with intestinal fibro...

Full description

Saved in:
Bibliographic Details
Main Authors: C. Yuan, W.-X. Chen, J.-S. Zhu, N.-W. Chen, Y.-M. Lu, Y.-X. Ou, H.-Q. Chen
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2013/617145
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685108355760128
author C. Yuan
W.-X. Chen
J.-S. Zhu
N.-W. Chen
Y.-M. Lu
Y.-X. Ou
H.-Q. Chen
author_facet C. Yuan
W.-X. Chen
J.-S. Zhu
N.-W. Chen
Y.-M. Lu
Y.-X. Ou
H.-Q. Chen
author_sort C. Yuan
collection DOAJ
description Prohibitin, which can inhibit oxidative stress and mitochondrial dysfunction, has been shown to have significant anti-inflammatory activities. Here, we investigate the effects of altering prohibitin levels in affected tissues in the interleukin-10 knockout (IL-10KO) mouse model with intestinal fibrosis. The aim of this study is to investigate the effects of IL-10 on prohibitin and the role of prohibitin in intestinal fibrosis of murine colitis. After the mice were treated with IL-10, prohibitin expression and localization were evaluated in IL-10KO and wild-type (WT, 129/SvEv) mice. The colon tissue was then investigated and the potential pathogenic molecular mechanisms were further studied. Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment. Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn’s disease and demonstrates a promising trend in decreasing tissue fibrosis. In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn’s disease. Interestingly, prohibitin may be a potential target for intestinal fibrosis associated with inflammatory bowel disease (IBD).
format Article
id doaj-art-c250f0e82a7b4bdb89e7fae218697704
institution DOAJ
issn 0962-9351
1466-1861
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-c250f0e82a7b4bdb89e7fae2186977042025-08-20T03:23:15ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/617145617145IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse ModelC. Yuan0W.-X. Chen1J.-S. Zhu2N.-W. Chen3Y.-M. Lu4Y.-X. Ou5H.-Q. Chen6Department of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaDepartment of General Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaProhibitin, which can inhibit oxidative stress and mitochondrial dysfunction, has been shown to have significant anti-inflammatory activities. Here, we investigate the effects of altering prohibitin levels in affected tissues in the interleukin-10 knockout (IL-10KO) mouse model with intestinal fibrosis. The aim of this study is to investigate the effects of IL-10 on prohibitin and the role of prohibitin in intestinal fibrosis of murine colitis. After the mice were treated with IL-10, prohibitin expression and localization were evaluated in IL-10KO and wild-type (WT, 129/SvEv) mice. The colon tissue was then investigated and the potential pathogenic molecular mechanisms were further studied. Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment. Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn’s disease and demonstrates a promising trend in decreasing tissue fibrosis. In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn’s disease. Interestingly, prohibitin may be a potential target for intestinal fibrosis associated with inflammatory bowel disease (IBD).http://dx.doi.org/10.1155/2013/617145
spellingShingle C. Yuan
W.-X. Chen
J.-S. Zhu
N.-W. Chen
Y.-M. Lu
Y.-X. Ou
H.-Q. Chen
IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
Mediators of Inflammation
title IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
title_full IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
title_fullStr IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
title_full_unstemmed IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
title_short IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model
title_sort il 10 treatment is associated with prohibitin expression in the crohn s disease intestinal fibrosis mouse model
url http://dx.doi.org/10.1155/2013/617145
work_keys_str_mv AT cyuan il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT wxchen il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT jszhu il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT nwchen il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT ymlu il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT yxou il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel
AT hqchen il10treatmentisassociatedwithprohibitinexpressioninthecrohnsdiseaseintestinalfibrosismousemodel